Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TUG-469
- Development stage
- Preclinical
- Lead developer
- University of Southern Denmark
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
TUG-469 is a selective, potent free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 of approximately 19 nM. It exhibits high selectivity (>200-fold) for FFA1 over the related free fatty acid receptor 4 (FFA4/GPR120). Developed by researchers at the University of Southern Denmark, TUG-469 stimulates glucose-stimulated insulin secretion (GSIS) from pancreatic beta-cells and has been shown to significantly improve glucose tolerance in pre-diabetic mouse models. It serves as a valuable tool compound in diabetes and metabolic research.
- Other names
- TUG469TUG-469TUG 469
02
Targets
FFAR1 (Free fatty acid receptor 1)
Beyond the preview
Go deeper on TUG-469.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TUG-469.